GHK-Cu, Epithalon, and SS-31: The Triple Anti-Aging Stack With One FDA-Approved Drug

On September 19, 2025, the FDA approved elamipretide, sold as Forzinity, as the first mitochondria-targeted therapeutic in US history. That makes SS-31 the only FDA-approved drug in the GHK-Cu, Epithalon, and SS-31 anti-aging stack. Most people running this protocol do not know that. It also means the legal path to sourcing it changed significantly, and not in the direction most people expect.

At the same time, a 2025 study in Biogerontology independently confirmed that Epithalon increased telomerase activity 26-fold in normal human epithelial cells under laboratory conditions. That is the first replication of Khavinson's original Russian findings by a Western research group. And GHK-Cu, after years on the FDA compounding ban list, was removed from Category 2 in April 2026 and is now heading toward a PCAC hearing. This stack is moving fast. Here is where each peptide stands, what the evidence actually shows, and the 12-week protocol that sequences all three correctly.

The reason to stack these three peptides is that each one targets a completely different aging mechanism. GHK-Cu works on which genes are switched on, turning tissue repair programs back up as they get quietly silenced with age. Epithalon works on telomeres, the protective caps on the ends of your chromosomes that get trimmed with every cell division, by switching on telomerase, the enzyme that rebuilds them. SS-31 works inside mitochondria, the tiny power plants in every cell, by binding to a fat called cardiolipin in their inner membrane and restoring the energy output that falls as that membrane takes oxidative damage over decades.

These pathways do not overlap. Running all three addresses the three best-documented molecular mechanisms of biological aging at the same time, without redundancy. The challenge is sequencing them correctly, because each peptide has a different optimal cycle structure.

What Makes GHK-Cu the Base Layer of Every Anti-Aging Stack?

GHK-Cu is a naturally occurring three-amino-acid peptide that carries copper and circulates in blood. Healthy adults in their twenties run around 200 nanograms per millilitre. By age 60 that is roughly 80, a 60 percent decline. It falls alongside the gradual switching-off of repair genes across nearly every tissue.

The 2018 analysis by Pickart and Margolina in the International Journal of Molecular Sciences (PMID 29986520) is the benchmark reference. They mapped GHK-Cu's effects on gene activity using the NCBI Gene Expression Omnibus database and reported changes across more than 4,000 human genes: collagen production, antioxidant defence, inflammation control, nerve growth signals, and dozens of repair pathways. That is an unusually broad footprint for one molecule.

"GHK is a naturally occurring plasma tripeptide that declines with age. It has the ability to promote wound healing, attract immune cells, foster blood vessel growth, and activate a broad regenerative program across human tissues."

Pickart and Margolina, International Journal of Molecular Sciences, 2018

A 2024 paper by Sarbaziha and Goldberg in PRIME Journal confirmed GHK-Cu increased collagen deposition in 70 percent of participants versus 50 percent for vitamin C and 40 percent for placebo at one month. A separate 2024 PubMed-indexed study (PMID 38879894) showed GHK-Cu reduced lung inflammation and scarring markers in an animal model of silica dust disease, by acting on one of the lung's own antioxidant enzymes. The lung data points to effects well beyond skin repair.

Why GHK-Cu Is Not Just a Skin Peptide

The cosmetics industry adopted GHK-Cu decades ago, which created the widespread perception that this is primarily a skin compound. That framing is wrong in a way that systematically undersells the peptide. The Pickart 2018 analysis showed those gene-activity changes in heart muscle, lung, nerve and liver cells, not only in the collagen-making cells of skin. The skin results are the most visible, which is why the consumer market went that direction. The systemic effects on gene expression are arguably more significant for longevity.

The practical implication: GHK-Cu works best as a continuous base layer, not a cycle compound. Unlike growth hormone secretagogues, there is no evidence of receptor downregulation with extended use. Most longevity protocols run it at 1-3 mg per day subcutaneously, or as a 0.25-1 percent topical concentration for skin-specific applications. The gene modulation effects appear to require sustained exposure rather than pulsed cycles.

GHK-Cu Regulatory Update: April 2026 Gray Zone

Injectable GHK-Cu was placed in FDA Category 2 (banned from compounding) in September 2023. On April 22, 2026, the FDA removed it from Category 2 following nominator withdrawals. Removal from Category 2 does not mean compounding is authorized. Injectable GHK-Cu is now in a regulatory gray zone, with PCAC review scheduled before February 2027. Topical GHK-Cu has always been permissible under cosmetics regulations and remains so. For the injectable form, a physician at a licensed compounding pharmacy with documented clinical justification is the appropriate path until that PCAC hearing resolves its status.

How Epithalon Extends Telomeres (And What the 2025 Independent Study Actually Found)

For three decades, almost all Epithalon research came from one institution: the St. Petersburg Institute of Bioregulation and Gerontology, under Vladimir Khavinson. The single-source problem was the main reason Western researchers remained skeptical. In 2025, that changed. Al-dulaimi, Thomas, Matta, and Roberts published a study in Biogerontology (PMC12411320) independently confirming that Epithalon switched on telomerase in normal human cells: a 4-fold increase in the collagen-making cells of skin and a 26-fold increase in the cells that line surfaces such as gut and airway. This was done in dishes, not in people, but it is the first confirmation of the core mechanism outside Russia.

The finding matters because of what telomerase does. Most of the cells in your body make almost none of it. Every time a cell divides, its telomeres shorten a little. After roughly 50 to 70 divisions the cell hits a wall and stops dividing altogether, and that stalled state is one of the main engines of tissue ageing. Epithalon appears to switch the rebuilding enzyme back on temporarily. A 2025 review by Araj and colleagues in International Journal of Molecular Sciences (PMC11943447) also describes a human study in 75 women where 20 days of Epithalon under the tongue raised melatonin production 1.6-fold, and a trial in 162 patients with an inherited retinal disease reporting better sharpness of vision and a wider field of view.

The Paradox: Epithalon Activates a Cancer Enzyme and Reduces Tumors Anyway

Here is the uncomfortable fact most Epithalon protocol guides skip: telomerase is how cancer cells become immortal. Tumour cells hijack telomerase to get past that wall and keep dividing forever. Switching it on in healthy cells uses the same enzyme. The obvious concern is that you might accelerate cancer risk while pursuing anti-aging benefits.

That is not what the Russian animal studies found. Khavinson's long-term studies in cancer-prone mouse models consistently showed Epithalon-treated animals developed fewer tumors, later in life, with slower progression. The 2025 IJMS review examined this paradox and proposed two explanations: Epithalon may sharpen the immune system's ability to spot and clear cells that have started going wrong, and it may switch telomerase on in a controlled, reversible way rather than the permanent switch-on cancer cells use. This is not settled science. No long-term human safety randomized controlled trial exists. But the animal data is consistent enough across multiple studies that the theoretical cancer concern has not materialized in the preclinical evidence available.

Epithalon Regulatory Update: PCAC Hearing July 24, 2026

Epithalon was placed in FDA Category 2 in September 2023 and removed from it in April 2026. It is now scheduled for PCAC review on July 24, 2026, as part of a two-day hearing that also covers BPC-157, TB-500, and Semax. Epithalon is being evaluated specifically for a potential insomnia indication, reflecting the documented melatonin pathway effects from the human circadian data. A favourable PCAC vote would start the formal rulemaking to add it to the 503A Bulk Drug Substances list. Note that the committee advises the FDA rather than binding it, so a favourable vote is a step rather than a decision. If you have been waiting for a clearer legal route to Epithalon in the US, that process is the one to follow.

SS-31 Is Now FDA-Approved. Here Is What That Means for the Anti-Aging Stack.

Most people running the GHK-Cu, Epithalon, SS-31 stack treat all three as research peptides in the same regulatory category. They are not. SS-31 (elamipretide) received FDA accelerated approval on September 19, 2025, under the brand name Forzinity, for improving muscle strength in patients with Barth syndrome. This makes it the first FDA-approved cardiolipin-directed mitochondrial therapeutic in US history, and the only FDA-approved compound in this stack.

The Barth syndrome approval was based on TAZPOWER (NCT03098797), a randomized controlled crossover trial in 12 patients with genetically confirmed Barth syndrome. The trial showed significant improvements in muscle strength and cardiac stroke volume over 168 weeks of open-label extension. A 2025 comprehensive review in International Journal of Molecular Sciences (Tung et al., PMC11816484) covers the full trial landscape for elamipretide, including the heart failure, macular degeneration, and primary mitochondrial myopathy trials.

The 2025 Aging Cell paper (PMC12151887) added important context for longevity use: 8 weeks of elamipretide in aged mice reduced frailty and improved how the heart moved and how long muscle lasted before tiring. It did not, however, move any of the biological-age readouts, neither the chemical marks on DNA that age clocks read nor the broader pattern of which genes were switched on. SS-31 improves how your mitochondria work without turning back your biological age score. That matters for how you think about its role in the stack. It addresses a real and significant mechanism of decline, but it is not a clock-resetter in the sense that some protocols imply.

Why SS-31 Works Where General Antioxidants Fail

Cardiolipin is a fat found nowhere in the cell except the inner membrane of mitochondria. It holds the energy-production machinery together in working assemblies. As cardiolipin takes oxidative damage with age, those assemblies come apart, energy production becomes less efficient, and cells throughout the body make less of it. SS-31 binds cardiolipin directly, holds its structure together, and restores the electrical gradient across the membrane that energy production runs on.

General antioxidants like CoQ10 and PQQ never reach that inner membrane in meaningful amounts. SS-31 does, by design. A 2013 paper by Birk and colleagues in the Journal of the American Society of Nephrology showed SS-31 restoring energy output in mitochondria starved of blood supply, and doing it by binding cardiolipin rather than mopping up free radicals generally. That targeting is why it has produced results in patient populations where broad antioxidants have not. MOTS-c targets a related mitochondrial pathway but through a different mechanism involving nuclear gene regulation rather than membrane structure.

What the Forzinity Approval Means for Off-Label Compounding Access

Here is the regulatory complication that has not fully reached the biohacking community: under FDA rules, compounding pharmacies generally cannot prepare a copy of a commercially available FDA-approved drug. Forzinity became commercially available from AnovoRx Specialty Pharmacy in December 2025. That means compounding SS-31 for off-label longevity use is now legally precarious in a way it was not when elamipretide was purely investigational. Some longevity clinics continue to source compounded elamipretide with off-label clinical justifications, but the legal exposure has increased significantly post-approval.

For people who want to use SS-31 within a clearly legal framework, the appropriate path is through a licensed physician who can justify clinical need against the approved indication or an investigational pathway. See the 2026 US peptide legal guide for the broader compounding access landscape. Gray-market vendor purchases of SS-31 are now more clearly outside the regulatory framework than before the approval.

The 12-Week Triple Stack Protocol: How to Sequence GHK-Cu, Epithalon, and SS-31

Most people run all three simultaneously on the assumption that more overlap means more anti-aging effect. That is not how this stack works. Epithalon is a pulse compound: its strongest telomere effects occur during and shortly after the 10-day cycle. Running it continuously does not add benefit. SS-31 produces functional improvements that plateau after 6-8 weeks without cycling. GHK-Cu has no known downregulation signal and works better with sustained continuous exposure.

The efficient approach: GHK-Cu as a continuous base layer throughout the year, Epithalon as a quarterly 10-day pulse, and SS-31 as two focused 6-8 week resets per year. Starting the SS-31 cycle in week 4 of the Epithalon quarter means GHK-Cu's gene activation program has had three weeks to establish a foundation of enhanced repair signaling before you layer mitochondrial optimization on top.

The overlap in weeks 4 to 10, when SS-31 is running and Epithalon has finished, is deliberate. No interactions between the three are known. GHK-Cu works at and outside the cell surface. Epithalon acts on the pineal gland and on signals reaching the cell nucleus. SS-31 works inside mitochondria. They do not cross, which is what makes combining them coherent in the first place.

Year-Round Protocol: What Comes After Week 12

After the first 12 weeks, GHK-Cu continues uninterrupted. Epithalon runs for 10 days each quarter: January, April, July, and October is a common schedule. SS-31 runs for 6-8 weeks twice per year. Winter timing for the first SS-31 cycle aligns with the period when mitochondrial function shows the most measurable decline in aging studies. A late summer or early fall cycle for the second supports recovery from the oxidative load that heat stress accumulates over summer months. These timing recommendations come from biological rhythm data and community protocol experience, not controlled trial evidence specifically on timing.

Which of the Three Clocks Is Running Fastest for You?

Not everyone ages at the same rate on all three pathways. Your genetics partly decides where you are most exposed and which peptide has the most ground to make up. That is the one practical thing this section is for: it tells you what to buy first, not whether the stack works.

If your telomere caps are the weak link, start with Epithalon. TERT is the gene for the enzyme that rebuilds those caps, and lower-activity versions mean they shorten faster than average, so there is more for Epithalon to do. The gene for the RNA template that same enzyme copies from, hTERC, points the same way. A family history of heart disease or early cancers can be part of that picture. The 2025 Biogerontology paper found the biggest telomerase response in the cells that started with the least, which fits the idea that it works hardest where there is most to fix.

If your repair and antioxidant programs run weak, start with GHK-Cu. FOXO3 is one of the best-studied longevity genes in human populations: certain versions of it turn up far more often in people who reach 100 than in everyone else, and those same versions look like the ones that respond most to the kind of gene-activity shift GHK-Cu produces. NRF2, the master switch for antioxidant genes, works the same way in reverse: a weak version means more headroom, because the peptide is turning up a system that was already underperforming.

If your mitochondria are the weak link, start with SS-31. Roughly 9 percent of people of European ancestry carry haplogroup J, a version of the small genome inside mitochondria that leaks more electrons at the first stage of energy production. That leak is precisely what SS-31 contains. A slow version of SOD2, the enzyme that clears the resulting damage, compounds the problem over decades. Decline also accelerates more sharply after 50 in people carrying variants that affect how new mitochondria are built and maintained. The MOTS-c article covers a related pathway in more detail. See also the DNA-first decision framework for a broader ranking before committing to all three compounds.

The 2026 anti-aging peptide review covers additional longevity compounds that complement this stack. The PeptidesDNA report reads these same variants and ranks the three clocks in the order they matter for you. For some people one clock is clearly running faster than the other two, and knowing which lets you front-load that peptide instead of paying for all three from week one.